STAT3 and Familial prostate cancer: We recently showed that small molecule inhibitors of STAT3 OPB-31121 and OPB-51602, which directly bind to the SH2 domain and effectively block global downstream signaling through multiple STAT3-dependent pathways, were very active in prostate cancer cell models and specifically highly effective on the CSC compartment (128, 155).